Logo image of RVMD

REVOLUTION MEDICINES INC (RVMD) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:RVMD - US76155X1000 - Common Stock

75.96 USD
-0.78 (-1.02%)
Last: 12/18/2025, 4:41:06 PM
75.96 USD
0 (0%)
After Hours: 12/18/2025, 4:41:06 PM

RVMD Key Statistics, Chart & Performance

Key Statistics
Market Cap14.68B
Revenue(TTM)N/A
Net Income(TTM)-600.09M
Shares193.32M
Float186.18M
52 Week High81.49
52 Week Low29.17
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-5.17
PEN/A
Fwd PEN/A
Earnings (Next)02-24 2026-02-24/amc
IPO2020-02-13
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


RVMD short term performance overview.The bars show the price performance of RVMD in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40 60 80

RVMD long term performance overview.The bars show the price performance of RVMD in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100 150 200

The current stock price of RVMD is 75.96 USD. In the past month the price increased by 7.64%. In the past year, price increased by 72.31%.

REVOLUTION MEDICINES INC / RVMD Daily stock chart

RVMD Latest News, Press Relases and Analysis

RVMD Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 23.58 393.81B
AMGN AMGEN INC 14.83 174.69B
GILD GILEAD SCIENCES INC 14.83 150.71B
VRTX VERTEX PHARMACEUTICALS INC 25.77 113.51B
REGN REGENERON PHARMACEUTICALS 16.63 78.69B
ALNY ALNYLAM PHARMACEUTICALS INC 776.55 52.32B
INSM INSMED INC N/A 35.52B
NTRA NATERA INC N/A 31.02B
BIIB BIOGEN INC 10.15 24.93B
UTHR UNITED THERAPEUTICS CORP 19.21 21.83B
EXAS EXACT SCIENCES CORP N/A 19.24B
INCY INCYTE CORP 15.16 19.10B

About RVMD

Company Profile

RVMD logo image Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. The company is headquartered in Redwood City, California and currently employs 700 full-time employees. The company went IPO on 2020-02-13. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).

Company Info

REVOLUTION MEDICINES INC

700 Saginaw Dr

Redwood City CALIFORNIA 94063 US

CEO: Mark A. Goldsmith

Employees: 700

RVMD Company Website

RVMD Investor Relations

Phone: 14157663638

REVOLUTION MEDICINES INC / RVMD FAQ

What does REVOLUTION MEDICINES INC do?

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. The company is headquartered in Redwood City, California and currently employs 700 full-time employees. The company went IPO on 2020-02-13. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).


Can you provide the latest stock price for REVOLUTION MEDICINES INC?

The current stock price of RVMD is 75.96 USD. The price decreased by -1.02% in the last trading session.


Does REVOLUTION MEDICINES INC pay dividends?

RVMD does not pay a dividend.


What is the ChartMill rating of REVOLUTION MEDICINES INC stock?

RVMD has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


On which exchange is RVMD stock listed?

RVMD stock is listed on the Nasdaq exchange.


What is the expected growth for RVMD stock?

The Revenue of REVOLUTION MEDICINES INC (RVMD) is expected to grow by 1279.08% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


Can you provide the market cap for REVOLUTION MEDICINES INC?

REVOLUTION MEDICINES INC (RVMD) has a market capitalization of 14.68B USD. This makes RVMD a Large Cap stock.


RVMD Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to RVMD. When comparing the yearly performance of all stocks, RVMD is one of the better performing stocks in the market, outperforming 95.63% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

RVMD Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to RVMD. While RVMD seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

RVMD Financial Highlights

Over the last trailing twelve months RVMD reported a non-GAAP Earnings per Share(EPS) of -5.17. The EPS decreased by -44.01% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -26.65%
ROE -37.58%
Debt/Equity 0.16
Chartmill High Growth Momentum
EPS Q2Q%-71.28%
Sales Q2Q%N/A
EPS 1Y (TTM)-44.01%
Revenue 1Y (TTM)-100%

RVMD Forecast & Estimates

27 analysts have analysed RVMD and the average price target is 81.55 USD. This implies a price increase of 7.36% is expected in the next year compared to the current price of 75.96.

For the next year, analysts expect an EPS growth of -59.96% and a revenue growth 1279.08% for RVMD


Analysts
Analysts87.41
Price Target81.55 (7.36%)
EPS Next Y-59.96%
Revenue Next Year1279.08%

RVMD Ownership

Ownership
Inst Owners100.6%
Ins Owners1.87%
Short Float %9.02%
Short Ratio7.36